Ninlib Nilotinib 150 mg Capsule

Medically reviewed by a registered oncology pharmacist. Content sourced from FDA prescribing information for Nilotinib, European Medicines Agency (EMA) assessment reports, NCCN CML treatment guidelines 2026, and peer-reviewed clinical trial data. Last updated: June 2026.

Ninlib 150mg is a generic Nilotinib capsule — the same active molecule as brand-name Tasigna (Novartis) — used to treat Philadelphia chromosome-positive chronic myeloid leukaemia (Ph+ CML) in adults. It is a second-generation BCR-ABL tyrosine kinase inhibitor (TKI) prescribed for newly diagnosed chronic phase CML and for patients who are resistant or intolerant to Imatinib (Gleevec). Manufactured by Hetero Drugs (WHO-GMP certified). Standard dose: 150mg or 300mg twice daily on an empty stomach. Priced at $643 per pack. Ships discreetly to USA, UK, UAE, and KSA with full customs documentation. Prescription required

Product Specification Table

Why Must Nilotinib Be Taken on an Empty Stomach?

Taking Nilotinib with food — especially a high-fat meal — significantly increases drug absorption. A high-fat meal can increase Nilotinib blood levels (AUC) by up to 82% compared to a fasted state. This elevated exposure substantially increases the risk of serious side effects including QT interval prolongation, which can cause life-threatening cardiac arrhythmias.  The strict rule: take Ninlib at least 2 hours before eating and wait at least 1 hour after taking your dose before eating. Swallow capsules whole with a full glass of water. Do not crush, chew, or open capsules.  Also avoid completely: grapefruit and grapefruit juice, Seville oranges, and starfruit — all of which inhibit CYP3A4 and can dramatically raise Nilotinib blood levels.

What Blood Tests and Monitoring Are Required With Nilotinib?

The following monitoring is mandatory during Nilotinib therapy — your oncologist will schedule these:  Before starting: ECG (baseline QTc interval), full blood count (FBC/CBC), liver function tests (LFTs), electrolytes (potassium and magnesium must be corrected before starting), lipid profile, fasting blood glucose.  During treatment: ECG repeated 7 days after initiation, then periodically. FBC and LFTs every 2 weeks for the first 2 months, then monthly. Blood glucose and lipid monitoring every 3 months. BCR-ABL transcript levels by PCR every 3 months to assess molecular response.

Is Ninlib as Effective as Tasigna?

Yes. Ninlib is a bioequivalent generic of Tasigna. Bioequivalence means that Ninlib delivers the same amount of Nilotinib into the bloodstream (within the standard 80–125% regulatory range) as the brand-name Tasigna when taken under the same conditions. The active molecule — Nilotinib — is chemically identical in both products. Hetero Drugs Ltd. manufactures Ninlib in a WHO-GMP certified facility, and the product meets international pharmaceutical quality standards.  For patients on long-term CML maintenance, switching from Tasigna to Ninlib (with oncologist approval) can reduce annual medication costs by 70–80% without any compromise in therapeutic outcome.

What Is the Difference Between Nilotinib 150mg and 200mg?

Ninlib is available in 150mg and 200mg capsule strengths. The strength used depends on your prescribed dose:  150mg capsules: Used for the standard 300mg twice-daily regimen in newly diagnosed Ph+ CML patients (2 × 150mg = 300mg per dose).  200mg capsules: Used for the 400mg twice-daily regimen in patients with resistant or intolerant CML (2 × 200mg = 400mg per dose).  Both strengths contain identical active ingredient. The capsule shell and excipients are the same. Do not substitute strengths without oncologist authorisation, as this changes total daily dose.

Can Nilotinib Cause Treatment-Free Remission (TFR)?

Yes — for a select group of patients who achieve a sustained deep molecular response (DMR), specifically MR4.5 (BCR-ABL transcript levels below 0.0032% IS) maintained for at least 2 years, stopping Nilotinib therapy under close medical supervision may be possible. This is called treatment-free remission (TFR) or 'functional cure' of CML.  The landmark ENESTfreedom trial demonstrated that approximately 48% of eligible patients who stopped Nilotinib maintained remission at 96 weeks. Patients must be closely monitored by PCR every 4–6 weeks for the first year after stopping, and every 3 months thereafter. If BCR-ABL levels rise above MR3 (major molecular response), Nilotinib should be restarted promptly — 97% of patients who restart achieve major molecular response again.  TFR is only appropriate for carefully selected patients under specialist oncologist supervision — it must never be self-initiated.

Why Order Nilotinib (Ninlib) From Milan Medicals?

• Genuine Hetero Drugs stock — factory sealed, batch number and expiry date verified on every pack
• 70–80% lower cost than brand-name Tasigna — same molecule, same outcome, sustainable for long-term CML therapy
• Full export documentation — HS codes, certificate of origin, pharmaceutical export permits for USA, UK, UAE, and KSA customs
• Discreet shipping — plain, unmarked outer packaging, no pharmaceutical branding or product names on the box
• Tracked international delivery — 10–15 days to USA, 3–7 days to UK, 7–10 days to UAE/KSA
• Secure payment — PayPal, bank transfer, Bitcoin (BTC), Ethereum (ETH)
• WhatsApp oncology support — prescription review, dosing queries, shipping tracking: +919911661996
• Also available: Nilotinib 200mg capsules for 400mg twice-daily regimens

How it works

Nilotinib is a precision-targeted kinase inhibitor. In CML, a chromosomal translocation (the Philadelphia chromosome) creates a fusion gene called BCR-ABL, which produces an abnormal protein that drives uncontrolled proliferation of cancerous white blood cells. Nilotinib works by binding tightly to the BCR-ABL protein and blocking its kinase activity — switching off the molecular signal that tells leukaemia cells to multiply.  Compared to first-generation Imatinib, Nilotinib binds to the BCR-ABL kinase domain with approximately 30 times greater potency. This increased binding affinity is why Nilotinib is effective in patients whose CML has developed resistance to Imatinib. Nilotinib also inhibits c-KIT and PDGFR-alpha/beta kinases, though its primary therapeutic effect is through BCR-ABL inhibition.  The result: a significant, measurable reduction in BCR-ABL transcript levels (measured by PCR), leading to haematological remission, cytogenetic remission, and — for many patients — deep molecular remission (MR4 or MR4.5) with the possibility of treatment-free remission in long-term responders.

Ninlib 150mg is a generic Nilotinib capsule — a second-generation BCR-ABL tyrosine kinase inhibitor (TKI) used to treat Philadelphia chromosome-positive chronic myeloid leukaemia (Ph+ CML) in adult patients. It contains the identical active molecule as Tasigna, the originator brand manufactured by Novartis, and is bioequivalent — meaning it reaches the same blood levels and produces the same clinical outcomes at a fraction of the cost.  Ninlib 150mg is indicated for: — Newly diagnosed adults with Ph+ CML in the chronic phase — Adults with Ph+ CML in the chronic phase who are resistant or intolerant to prior therapy including Imatinib (Gleevec/Glivec) — Adults with Ph+ CML in the accelerated phase who are resistant or intolerant to prior therapy including Imatinib  Ninlib is manufactured by Hetero Drugs Ltd. — one of India's largest WHO-GMP certified pharmaceutical exporters — and shipped internationally to patients in the USA, UK, UAE, and KSA.

Dose depends on clinical indication and is always set by the treating oncologist:  Newly diagnosed Ph+ CML (chronic phase): 300mg taken orally twice daily, approximately 12 hours apart, on an empty stomach. Each dose of 300mg = 2 capsules of Ninlib 150mg.  Resistant or intolerant Ph+ CML (chronic or accelerated phase): 400mg taken orally twice daily, approximately 12 hours apart, on an empty stomach. Each dose of 400mg requires the 200mg strength capsule — note that the 150mg capsule is used for newly diagnosed patients or as directed by an oncologist for specific dosing regimens.  Do not adjust the dose without oncologist guidance. Dose reductions may be required for QT prolongation, hepatic impairment, or haematological toxicity.

How to Store Ninlib Nilotinib 150mg Capsules?

Store at room temperature between 20°C and 25°C (68°F–77°F). Keep in the original sealed blister pack until the time of use. Protect from light, heat, and moisture. Do not store in bathrooms or near kitchen sinks. Keep out of reach of children and pets. Do not use after the expiry date printed on the pack. Do not dispose of medicines via wastewater or household waste.

Common side effects (affecting more than 10% of patients): nausea, rash, headache, fatigue, pruritus (itching), vomiting, constipation, diarrhoea, thrombocytopaenia (low platelets), neutropaenia (low white blood cells), elevated liver enzymes (ALT/AST), elevated bilirubin, elevated lipase.  Serious side effects requiring immediate medical attention: — QT prolongation and sudden cardiac death: ECG and electrolyte monitoring (potassium, magnesium) required before starting treatment and periodically during treatment. — Cardiovascular events: peripheral arterial occlusive disease (PAOD), ischaemic heart disease, and ischaemic cerebrovascular events have been reported — risk increases with duration of therapy. — Pancreatitis: elevated lipase is common; symptomatic pancreatitis is rare but requires dose interruption. — Hepatotoxicity: liver function tests must be monitored regularly. — Haemorrhage: including gastrointestinal and CNS bleeds. — Tumour lysis syndrome (rare): monitor uric acid and renal function at treatment initiation.  This medication requires continuous specialist monitoring. Never take without direct oncologist supervision.

No. Nilotinib is classified as FDA Pregnancy Category D (evidence of human fetal risk). Animal studies and case reports show it causes fetal harm. Women of childbearing potential must use effective contraception during treatment and for at least 14 days after the last dose. Nilotinib may also impair male fertility. Breastfeeding is contraindicated during treatment.  If pregnancy occurs during Nilotinib therapy, the treating oncologist must be informed immediately to assess the risk-benefit balance and consider alternative treatment options.